FAFederico Mario Aletti
Federico Mario Aletti
*This is an algorithmically generated author record based on publicly available information.
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Federico Mario Aletti has a total of 69 co-authors. Here are the top co-authors by number of shared publications:
- Faezeh Darbaniyan
University of Texas MD Anderson Cancer Center
3 shared publications - Sattva Swarup Neelapu
The University of Texas MD Anderson Cancer Center
3 shared publications - Abdur Rehman
University of Texas MD Anderson Cancer Center
2 shared publications - Cao Cuong Le
University of Texas MD Anderson Cancer Center
2 shared publications - Chun-Yen Lin
University of Texas MD Anderson Cancer Center
2 shared publications - Francisco Vega
The University of Texas MD Anderson Cancer Center
2 shared publications
Latest Publications
- Open Access
- 28 September 2026
- Published by Binaytara in International Journal of Cancer Care and Delivery
- Vol. 6 (Supplement) , 1-2
Germline Predisposition to Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS) after CAR T Cell Therapy for Lymphoma and Myeloma
From the 2026 National Summit on Hematologic Cancers
- 28 September 2026
- Published by Binaytara in International Journal of Cancer Care and Delivery
- Vol. 6 (Supplement) , 1-2
Open AccessGermline Predisposition to Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS) after CAR T Cell Therapy for Lymphoma and Myeloma
From the 2026 National Summit on Hematologic Cancers
- Open Access
- 25 September 2026
- Published by Binaytara in International Journal of Cancer Care and Delivery
- Vol. 6 (Supplement) , 1-2
A novel KIR3DL2-directed CAR T-cell therapy for cutaneous and systemic T-cell lymphomas
From the 2026 National Summit on Hematologic Cancers
- 25 September 2026
- Published by Binaytara in International Journal of Cancer Care and Delivery
- Vol. 6 (Supplement) , 1-2
Open AccessA novel KIR3DL2-directed CAR T-cell therapy for cutaneous and systemic T-cell lymphomas
From the 2026 National Summit on Hematologic Cancers
- Open Access
- 25 September 2026
- Published by Binaytara in International Journal of Cancer Care and Delivery
- Vol. 6 (Supplement) , 1-2
A Novel CD94-targeting CAR T Cell Therapy for Cytotoxic Subtypes of T/NK-cell Malignancies
From the 2026 National Summit on Hematologic Cancers
- 25 September 2026
- Published by Binaytara in International Journal of Cancer Care and Delivery
- Vol. 6 (Supplement) , 1-2
Open AccessA Novel CD94-targeting CAR T Cell Therapy for Cytotoxic Subtypes of T/NK-cell Malignancies
From the 2026 National Summit on Hematologic Cancers